Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,652JPY
1:00am EST
Change (% chg)

¥18 (+0.70%)
Prev Close
¥2,633
Open
¥2,655
Day's High
¥2,662
Day's Low
¥2,636
Volume
1,387,500
Avg. Vol
2,384,466
52-wk High
¥2,800
52-wk Low
¥2,284

Latest Key Developments (Source: Significant Developments)

Daiichi Sankyo to repurchase shares for up to 50 bln yen
Tuesday, 31 Oct 2017 12:33am EDT 

Oct 31(Reuters) - Daiichi Sankyo Co Ltd <4568.T>:Says it plans to buy back up to 28 million shares, representing 4.2 percent of outstanding, for up to 50 billion yen, during period from Nov. 1 to March 23, 2018.  Full Article

Daiichi Sankyo to buy back up to 50 bln yen of stock
Tuesday, 31 Oct 2017 12:00am EDT 

Oct 31 (Reuters) - Daiichi Sankyo <4568.T>::Says it will buy back up to 50 billion yen ($442 million) of stock through March 23.  Full Article

Inovalon enters into agreement with Daiichi Sankyo Inc
Thursday, 21 Sep 2017 07:55am EDT 

Sept 21 (Reuters) - Inovalon Holdings Inc :Inovalon announces agreement with daiichi sankyo, inc. To support outcomes-based contracting.Inovalon Holdings -entered into agreement with Daiichi Sankyo to understand potential role of abuse-deterrent formulations of opioid medications.  Full Article

Daiichi Sankyo late-stage trial positive on diabetic pain drug
Thursday, 31 Aug 2017 07:00am EDT 

Aug 31 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>:Daiichi Sankyo announces positive top-line results from Phase 3 clinical trial evaluating mirogabalin in diabetic peripheral neuropathic pain.Daiichi Sankyo Co Ltd - ‍preliminary and ongoing analyses indicated no significant safety concerns in reducer trial​.  Full Article

AstraZeneca has no comment on report it sought to buy Daiichi Sankyo
Thursday, 31 Aug 2017 02:43am EDT 

Aug 31 (Reuters) - AstraZeneca Plc :Britain's AstraZeneca has no comment on report it sought to buy Japan's Daiichi Sankyo <<<4568.T>>> last year - spokeswoman.  Full Article

Bristol-Myers Squibb and Daiichi Sankyo collaborate to evaluate Opdivo (Nivolumab) and DS-8201
Monday, 28 Aug 2017 04:01pm EDT 

Aug 28 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>:Bristol-Myers Squibb and Daiichi Sankyo announce research collaboration to evaluate Opdivo (Nivolumab) and DS-8201 in HER2-expressing breast and bladder cancers.Bristol-Myers Squibb Co - ‍Study is expected to begin enrollment in Q1 of 2018 in US and Europe​.Bristol-Myers Squibb Co - ‍Under terms of agreement, Daiichi Sankyo will be sponsor conducting trial​.  Full Article

Daiichi Sankyo enters agreement with Boston Pharmaceuticals
Monday, 28 Aug 2017 08:00am EDT 

Aug 28 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>:Daiichi Sankyo enters worldwide licensing agreement with Boston Pharmaceuticals for a highly selective RET inhibitor for solid tumors.Daiichi Sankyo Co Ltd - financial terms of agreement were not disclosed.Daiichi Sankyo Co Ltd - grants Boston Pharmaceuticals worldwide rights for research, development, manufacturing and commercialization of DS-5010.  Full Article

Daiichi Sankyo and unit says settlement agreement on u.s. products liability litigation
Tuesday, 1 Aug 2017 10:26pm EDT 

Aug 2 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>:* Says it and U.S.-based unit Daiichi Sankyo, Inc. have agreed to enter into a program to settle, on behalf of all defendants, pending product liability litigation against various Daiichi Sankyo and Forest entities .* According to the settlement agreement, it and unit will pay settlement fund of $300 million to plaintiffs.  Full Article

Daiichi Sankyo announces settlement on U.S. products liability litigation
Tuesday, 1 Aug 2017 12:14pm EDT 

Aug 1 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::Announces settlement agreement on U.S. Products liability litigation​.Impact to financial position of company is not considered material from agreement​.Claimants who meet specified criteria will receive payouts from settlement fund, which is capped at $300 million.  Full Article

EU Medicines Agency recommends approval of Novartis' leukaemia drug
Friday, 21 Jul 2017 07:37am EDT 

July 21 (Reuters) - EU Medicines Agency: :EU Medicines Agency recommendations For July 2017.EU Medicines Agency recommends approval of Pfizer Inc and Merck KGAA Avelumab drug for cell carcinoma‍​.EU Medicines Agency recommends approval of Sanofi and Regeneron Dupixent drug for severe eczema.EU Medicines Agency recommends approval Of Roche Tecentriq drug for drug for bladder and lung cancer‍​.EU Medicines Agency recommends approval Of Advanced Accelerator Applications Lutathera drug for gastroenteropancreatic neuroendocrine tumours.EU Medicines Agency recommends against approval of Nektar Therapeutics and Daiichi Sankyo Onzeald drug for breast cancer.EU Medicines Agency recommends approval of Novartis Rydapt drug for leukaemia.  Full Article

BRIEF- Daiichi Sankyo to repurchase shares for up to 50 bln yen

* Says it plans to buy back up to 28 million shares, representing 4.2 percent of outstanding, for up to 50 billion yen, during period from Nov. 1 to March 23, 2018